These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24983389)

  • 21. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of 'test and treat' policy for antiretroviral therapy among heterosexual HIV population in India.
    Singh M; Sharma A; Bahuguna P; Jyani G; Prinja S
    Indian J Med Res; 2022 Jun; 156(6):705-714. PubMed ID: 37056069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting HIV care costs using CD4 counts from clinical trials.
    Hill A; Gebo K
    Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV.
    Gopalappa C; Stover J; Shaffer N; Mahy M
    AIDS; 2014 Jan; 28 Suppl 1():S5-14. PubMed ID: 24468947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda.
    Jain V; Chang W; Byonanebye DM; Owaraganise A; Twinomuhwezi E; Amanyire G; Black D; Marseille E; Kamya MR; Havlir DV; Kahn JG
    PLoS One; 2015; 10(12):e0143433. PubMed ID: 26632823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in antiretroviral therapy guidelines: implications for public health policy and public purses.
    Hamilton A; Garcia-Calleja JM; Vitoria M; Gilks C; Souteyrand Y; De Cock K; Crowley S
    Sex Transm Infect; 2010 Oct; 86(5):388-90. PubMed ID: 20876757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
    Mauskopf J; Brogan AJ; Talbird SE; Martin S
    AIDS; 2012 Jan; 26(3):355-64. PubMed ID: 22089378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies.
    Kimaro GD; Mfinanga S; Simms V; Kivuyo S; Bottomley C; Hawkins N; Harrison TS; Jaffar S; Guinness L;
    PLoS One; 2017; 12(2):e0171917. PubMed ID: 28234969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
    Medina Lara A; Kigozi J; Amurwon J; Muchabaiwa L; Nyanzi Wakaholi B; Mujica Mota RE; Walker AS; Kasirye R; Ssali F; Reid A; Grosskurth H; Babiker AG; Kityo C; Katabira E; Munderi P; Mugyenyi P; Hakim J; Darbyshire J; Gibb DM; Gilks CF;
    PLoS One; 2012; 7(4):e33672. PubMed ID: 22545079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings.
    Athan E; O'Brien DP; Legood R
    AIDS; 2010 Jul; 24(12):1887-95. PubMed ID: 20543661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics.
    Tran BX; Ohinmaa A; Duong AT; Nguyen LT; Vu PX; Mills S; Houston S; Jacobs P
    Drug Alcohol Depend; 2012 Oct; 125(3):260-6. PubMed ID: 22436971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda.
    McCreesh N; Andrianakis I; Nsubuga RN; Strong M; Vernon I; McKinley TJ; Oakley JE; Goldstein M; Hayes R; White RG
    BMC Infect Dis; 2017 May; 17(1):322. PubMed ID: 28468605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau (ESTHER) substudy].
    Suzan-Monti M; Blanche J; Boyer S; Kouanfack C; Delaporte E; Bonono RC; Carrieri PM; Protopopescu C; Laurent C; Spire B;
    HIV Med; 2015 May; 16(5):307-18. PubMed ID: 25721267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial.
    Long LC; Maskew M; Brennan AT; Mongwenyana C; Nyoni C; Malete G; Sanne I; Fox MP; Rosen S
    AIDS; 2017 Jul; 31(11):1611-1619. PubMed ID: 28463879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
    Meyer-Rath G; Pienaar J; Brink B; van Zyl A; Muirhead D; Grant A; Churchyard G; Watts C; Vickerman P
    PLoS Med; 2015 Sep; 12(9):e1001869. PubMed ID: 26327271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of socioeconomic factors on the healthcare costs of people living with HIV in Turkey.
    Özdemir HÖ; Tosun S; Kabadurmuş FNK; Özdemir D
    BMC Public Health; 2020 Mar; 20(1):368. PubMed ID: 32197598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia.
    Marseille E; Giganti MJ; Mwango A; Chisembele-Taylor A; Mulenga L; Over M; Kahn JG; Stringer JS
    PLoS One; 2012; 7(12):e51993. PubMed ID: 23284843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.